SCHEMBL23218295

SCHEMBL23218295

CCOC(=O)Cc1ccccc1OCc1c(C(=O)O)oc2ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
LMNA P02545 2/20 0.41
MCL1 Q07820 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.39
TBXAS1 P24557 1/20 0.39
EDNRA P25101 1/20 0.39
BCL2 P10415 1/20 0.39
BCL2L1 Q07817 1/20 0.39
BAD Q92934 1/20 0.39
MEN1 O00255 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
PLK1 P53350 1/20 0.38
ADORA2A P29274 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592706 1.00 TSHR (0.41) TSHRLMNAMCL1ALDH1A1HPGD
SCHEMBL29852813 0.92 TSHR (0.49) TSHRLMNAALDH1A1KDM4EKMT2A
SCHEMBL29852615 0.92 MAPT (0.45) TSHRLMNAALDH1A1KDM4EKMT2A
SCHEMBL23218747 0.92 TSHR (0.49) TSHRLMNAALDH1A1KDM4EKMT2A
SCHEMBL23219253 0.92 MAPT (0.45) TSHRLMNAALDH1A1KDM4EKMT2A
SCHEMBL23218382 0.92 CA12 (0.42) TSHRLMNAALDH1A1HPGDKDM4E
SCHEMBL29853250 0.89 TBXAS1 (0.41) TSHRLMNAKMT2AMAPTTBXAS1
SCHEMBL23219259 0.89 TBXAS1 (0.41) TSHRLMNAKMT2AMAPTTBXAS1
SCHEMBL23218650 0.88 TSHR (0.42) TSHRLMNAALDH1A1HPGDKDM4E
SCHEMBL29852865 0.88 TSHR (0.42) TSHRLMNAALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885LMNA 1698/4885MCL1 2141/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885LMNA 1844/4885MCL1 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.